Reduced anticoagulation targets in extracorporeal life support
This research is investigating whether using carefully controlled, lower strengths of blood-thinning medicines, such as Heparin and Nadroparin, can be beneficial for patients who need a special type of life support called ECMO. ECMO is a machine that takes over the work of the heart and lungs. The main goal is to find out if these lower doses can significantly reduce serious problems like major bleeding (including strokes caused by bleeding), dangerous blood clots (like strokes from clots, or clots affecting limbs or the machine itself), and ultimately improve a patient's chances of survival up to 6 months after treatment. This is a Phase III study, meaning it's comparing a new approach to what's currently done, to see if it's better.
At a glance
What is this study about?
This study, called "Reduced anticoagulation targets in extracorporeal life support," is looking into how we use medicines that thin the blood for people who are on a special type of life support called ECMO. ECMO stands for Extracorporeal Membrane Oxygenation, and it's a machine that helps severe heart and lung problems when the body can’t do it on its own. While ECMO is life-saving, patients on it need blood thinners to stop clots forming in the machine or their body, but these medicines can also increase the risk of serious bleeding.
The researchers want to see if using a lower, but still safe, dose of these blood-thinning medicines (specifically Heparin and Nadroparin) can prevent some of the serious side effects. They are particularly interested in whether it can reduce major bleeding, including bleeding in the brain (a type of stroke), and also stop serious blood clots from forming. These clots could cause problems like another type of stroke, or issues with blood flow to limbs, or even stop the ECMO machine itself from working properly.
Ultimately, the study aims to understand if this new approach to blood-thinning can lead to better overall results for patients, including better survival rates six months after their treatment. This is a very important study because it could help doctors make ECMO treatment safer and more effective for severely ill patients in the future.
Key takeaways
- The study explores safer doses of blood thinners for ECMO patients.
- It aims to reduce major bleeding and dangerous blood clots.
- The goal is to improve outcomes and survival rates.
- Participation involves close monitoring as part of routine care.
- Results could make ECMO treatment more effective for future patients.
Who may be eligible?
This study is looking for adults aged 18 and over, of any gender, who are receiving ECMO treatment at one of the hospitals taking part in the study.
However, there are a few reasons why someone might not be able to join. For example, if the ECMO machine is only being used for a very short time to help during a specific medical procedure, like a complex heart intervention or during surgery, then that person would not be included.
The research staff will talk to you, or your legal representative if you're too unwell, to explain everything fully and get your permission to take part, either at the time or later, if you or they agree.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I (or the patient) aged 18 or older?
- Am I (or the patient) currently receiving ECMO treatment?
- Is this ECMO treatment for ongoing heart or lung failure, not just for a short procedure?
- Am I (or the patient's legal representative) willing to consider contributing anonymous data from my care?
What does participation involve?
If you or your loved one decides to participate, the study involves close monitoring of your health and how the blood-thinning medicines are working. The doctors will follow a specific plan for giving you either Heparin or Nadroparin at a certain strength, and they'll regularly check for any bleeding or blood clot issues.
Hospital staff will collect information from your routine blood tests and medical notes. You won't have any extra hospital visits just for the study, as all assessments will be done while you are receiving ECMO care. After the ECMO treatment, researchers will track your health for up to six months, which might include looking at your quality of life during this period. The total duration of your involvement will therefore be up to six months after your ECMO treatment ends.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is ECMO?
ECMO is a life support machine that takes over the work of your heart and lungs when they are too sick to function on their own. It helps your body get enough oxygen.
Why do patients on ECMO need blood thinners?
Blood thinners are given to stop blood clots from forming in the ECMO machine itself or in your body, which can be very dangerous. However, they can also increase the risk of bleeding.
What are Heparin and Nadroparin?
These are common medicines used to thin the blood and prevent clots. This study is looking at using them at carefully chosen lower strengths.
Will I get extra tests or procedures if I join?
No, you won't have any extra tests or procedures just for the study. All checks will be part of your usual medical care while on ECMO.
What if I change my mind about taking part?
You are free to stop participating in the study at any time, for any reason, and it will not affect your medical care in any way.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.